ArticleCancer2014

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.

Yesid Alvarado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.